Literature DB >> 24487271

Clinical, serologic, and genetic factors associated with pyoderma gangrenosum and erythema nodosum in inflammatory bowel disease patients.

Adam Weizman1, Brian Huang, Dror Berel, Stephan R Targan, Marla Dubinsky, Phillip Fleshner, Andrew Ippoliti, Manreet Kaur, Deepa Panikkath, Steve Brant, Ioannis Oikonomou, Rick Duerr, John Rioux, Mark Silverberg, Jerome I Rotter, Eric Vasiliauskas, Talin Haritunians, David Shih, Dalin Li, Gil Y Melmed, Dermot P B McGovern.   

Abstract

BACKGROUND: Pyoderma gangrenosum (PG) and erythema nodosum (EN) are the most common cutaneous manifestations of inflammatory bowel disease (IBD) but little is known regarding their etiopathogenesis.
METHODS: We performed a case-control study comparing characteristics between IBD patients with a documented episode of PG (PG+) and/or EN (EN+) with those without PG (PG-) and EN (EN-). Data on clinical features were obtained by chart review. IBD-related serology was determined using enzyme-linked immunosorbent assay and genome-wide data generated using Illumina technology. Standard statistical tests for association were used.
RESULTS: We identified a total of 92 cases of PG and 103 cases of EN with genetic and clinical characteristics, of which 64 PG and 55 EN cases were available for serological analyses. Fewer male subjects were identified in the PG(+) (odds ratio 0.6, P = 0.009) and EN(+) groups (odds ratio 0.31, P = 0 < 0.0001). Colonic disease, previous IBD-related surgery, and noncutaneous extra-intestinal manifestations were more common among both PG(+) and EN(+) patients compared with controls. PG(+) was associated with anti-nuclear cytoplasmic antibody seropositivity (P = 0.03) and higher anti-nuclear cytoplasmic antibody level (P = 0.02) in Crohn's disease. Genetic associations with PG included known IBD loci (IL8RA [P = 0.00003] and PRDM1 [0.03]) as well as with USP15 (4.8 × 10) and TIMP3 (5.6 ×10). Genetic associations with EN included known IBD susceptibility genes (PTGER4 [P = 8.8 × 10], ITGAL [0.03]) as well as SOCS5 (9.64 × 10), CD207 (3.14 × 10), ITGB3 (7.56 × 10), and rs6828740 (4q26) (P < 5.0 × 10). Multivariable models using clinical, serologic, and genetic parameters predicted PG (area under the curve = 0.8) and EN (area under the curve = 0.97).
CONCLUSION: Cutaneous manifestations in IBD are associated with distinctive genetic characteristics and with the similar clinical characteristics, including the development of other extra-intestinal manifestations suggesting shared and distinct etiologies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24487271      PMCID: PMC4046633          DOI: 10.1097/01.MIB.0000442011.60285.68

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  52 in total

1.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology.

Authors:  Mark S Silverberg; Jack Satsangi; Tariq Ahmad; Ian D R Arnott; Charles N Bernstein; Steven R Brant; Renzo Caprilli; Jean-Frédéric Colombel; Christoph Gasche; Karel Geboes; Derek P Jewell; Amir Karban; Edward V Loftus; A Salvador Peña; Robert H Riddell; David B Sachar; Stefan Schreiber; A Hillary Steinhart; Stephan R Targan; Severine Vermeire; B F Warren
Journal:  Can J Gastroenterol       Date:  2005-09       Impact factor: 3.522

Review 2.  Extraintestinal manifestations in inflammatory bowel disease.

Authors:  Silvio Danese; Stefano Semeraro; Alfredo Papa; Italia Roberto; Franco Scaldaferri; Giuseppe Fedeli; Giovanni Gasbarrini; Antonio Gasbarrini
Journal:  World J Gastroenterol       Date:  2005-12-14       Impact factor: 5.742

3.  Fucosyltransferase 2 (FUT2) non-secretor status is associated with Crohn's disease.

Authors:  Dermot P B McGovern; Michelle R Jones; Kent D Taylor; Kristin Marciante; Xiaofei Yan; Marla Dubinsky; Andy Ippoliti; Eric Vasiliauskas; Dror Berel; Carrie Derkowski; Deb Dutridge; Phil Fleshner; David Q Shih; Gil Melmed; Emebet Mengesha; Lily King; Sheila Pressman; Talin Haritunians; Xiuqing Guo; Stephan R Targan; Jerome I Rotter
Journal:  Hum Mol Genet       Date:  2010-06-22       Impact factor: 6.150

Review 4.  Pyoderma gangrenosum: classification and management.

Authors:  F C Powell; W P Su; H O Perry
Journal:  J Am Acad Dermatol       Date:  1996-03       Impact factor: 11.527

Review 5.  TGR5 sequence variation in primary sclerosing cholangitis.

Authors:  Johannes R Hov; Verena Keitel; Erik Schrumpf; Dieter Häussinger; Tom H Karlsen
Journal:  Dig Dis       Date:  2011-06-17       Impact factor: 2.404

6.  Extracolonic diagnoses in ulcerative colitis: an epidemiological study.

Authors:  U Monsén; J Sorstad; G Hellers; C Johansson
Journal:  Am J Gastroenterol       Date:  1990-06       Impact factor: 10.864

7.  The effect of infliximab on extraintestinal manifestations of Crohn's disease.

Authors:  Ilana Kaufman; Dan Caspi; Dror Yeshurun; Iris Dotan; Michael Yaron; Ori Elkayam
Journal:  Rheumatol Int       Date:  2004-08-12       Impact factor: 2.631

Review 8.  Prediction of progression: nomograms of clinical utility.

Authors:  Michael W Kattan; Peter T Scardino
Journal:  Clin Prostate Cancer       Date:  2002-09

9.  Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47.

Authors:  Carl A Anderson; Gabrielle Boucher; Charlie W Lees; Andre Franke; Mauro D'Amato; Kent D Taylor; James C Lee; Philippe Goyette; Marcin Imielinski; Anna Latiano; Caroline Lagacé; Regan Scott; Leila Amininejad; Suzannah Bumpstead; Leonard Baidoo; Robert N Baldassano; Murray Barclay; Theodore M Bayless; Stephan Brand; Carsten Büning; Jean-Frédéric Colombel; Lee A Denson; Martine De Vos; Marla Dubinsky; Cathryn Edwards; David Ellinghaus; Rudolf S N Fehrmann; James A B Floyd; Timothy Florin; Denis Franchimont; Lude Franke; Michel Georges; Jürgen Glas; Nicole L Glazer; Stephen L Guthery; Talin Haritunians; Nicholas K Hayward; Jean-Pierre Hugot; Gilles Jobin; Debby Laukens; Ian Lawrance; Marc Lémann; Arie Levine; Cecile Libioulle; Edouard Louis; Dermot P McGovern; Monica Milla; Grant W Montgomery; Katherine I Morley; Craig Mowat; Aylwin Ng; William Newman; Roel A Ophoff; Laura Papi; Orazio Palmieri; Laurent Peyrin-Biroulet; Julián Panés; Anne Phillips; Natalie J Prescott; Deborah D Proctor; Rebecca Roberts; Richard Russell; Paul Rutgeerts; Jeremy Sanderson; Miquel Sans; Philip Schumm; Frank Seibold; Yashoda Sharma; Lisa A Simms; Mark Seielstad; A Hillary Steinhart; Stephan R Targan; Leonard H van den Berg; Morten Vatn; Hein Verspaget; Thomas Walters; Cisca Wijmenga; David C Wilson; Harm-Jan Westra; Ramnik J Xavier; Zhen Z Zhao; Cyriel Y Ponsioen; Vibeke Andersen; Leif Torkvist; Maria Gazouli; Nicholas P Anagnou; Tom H Karlsen; Limas Kupcinskas; Jurgita Sventoraityte; John C Mansfield; Subra Kugathasan; Mark S Silverberg; Jonas Halfvarson; Jerome I Rotter; Christopher G Mathew; Anne M Griffiths; Richard Gearry; Tariq Ahmad; Steven R Brant; Mathias Chamaillard; Jack Satsangi; Judy H Cho; Stefan Schreiber; Mark J Daly; Jeffrey C Barrett; Miles Parkes; Vito Annese; Hakon Hakonarson; Graham Radford-Smith; Richard H Duerr; Séverine Vermeire; Rinse K Weersma; John D Rioux
Journal:  Nat Genet       Date:  2011-02-06       Impact factor: 38.330

10.  Skin manifestations of inflammatory bowel disease.

Authors:  Brian L Huang; Stephanie Chandra; David Quan Shih
Journal:  Front Physiol       Date:  2012-02-06       Impact factor: 4.566

View more
  18 in total

1.  Adalimumab plus topical tacrolimus for the treatment of pyoderma gangrenosum: Report of a case.

Authors:  Claudio Marasca; Giuseppina Fontanella; Maria C Annunziata; Dario Marasca; Gabriella Fabbrocini
Journal:  Int Wound J       Date:  2019-04-01       Impact factor: 3.315

Review 2.  Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease.

Authors:  Jurij Hanzel; Christopher Ma; Niels Vande Casteele; Reena Khanna; Vipul Jairath; Brian G Feagan
Journal:  Drugs       Date:  2021-01-05       Impact factor: 9.546

3.  Personalized Medicine in Inflammatory Bowel Disease.

Authors:  Dermot McGovern
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-10

4.  A Wound Care Specialist's Approach to Pyoderma Gangrenosum.

Authors:  David Croitoru; Sheida Naderi-Azad; Muskaan Sachdeva; Vincent Piguet; Afsaneh Alavi
Journal:  Adv Wound Care (New Rochelle)       Date:  2020-06-16       Impact factor: 4.730

Review 5.  Skin Manifestations of Inflammatory Bowel Disease.

Authors:  Thomas Greuter; Alexander Navarini; Stephan R Vavricka
Journal:  Clin Rev Allergy Immunol       Date:  2017-12       Impact factor: 8.667

Review 6.  Current clinical issue of skin lesions in patients with inflammatory bowel disease.

Authors:  Tomoya Iida; Tokimasa Hida; Minoru Matsuura; Hisashi Uhara; Hiroshi Nakase
Journal:  Clin J Gastroenterol       Date:  2019-03-05

Review 7.  Genetics of Inflammatory Bowel Diseases.

Authors:  Dermot P B McGovern; Subra Kugathasan; Judy H Cho
Journal:  Gastroenterology       Date:  2015-08-07       Impact factor: 22.682

Review 8.  Management of pyoderma gangrenosum.

Authors:  Alexandra Teagle; Rachel Hargest
Journal:  J R Soc Med       Date:  2014-06-09       Impact factor: 5.344

9.  Assessment of extraintestinal manifestations in inflammatory bowel diseases: A systematic review and a proposed guide for clinical trials.

Authors:  Lucas Guillo; Ferdinando D'Amico; Mélanie Serrero; Karine Angioi; Damien Loeuille; Antonio Costanzo; Silvio Danese; Laurent Peyrin-Biroulet
Journal:  United European Gastroenterol J       Date:  2020-08-10       Impact factor: 4.623

10.  Low Rates of Dermatologic Care and Skin Cancer Screening Among Inflammatory Bowel Disease Patients.

Authors:  Alyce Anderson; Laura K Ferris; Benjamin Click; Claudia Ramos-Rivers; Ioannis E Koutroubakis; Jana G Hashash; Michael Dunn; Arthur Barrie; Marc Schwartz; Miguel Regueiro; David G Binion
Journal:  Dig Dis Sci       Date:  2018-04-30       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.